In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice
Loading...
Files
Published Version
Date
2013-02-01
Authors
Campion, Alicia M.
Casey, Pat G.
Field, Des
Cotter, Paul D.
Hill, Colin
Ross, R. Paul
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central Ltd.
Published Version
Abstract
Background: Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo. Results: Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model. More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 × 105 cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen. Conclusion: This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.
Description
Keywords
Antimicrobial , Lantibiotic , Bacteriocin , Peptide engineering , Mutagenesis , Nisin
Citation
CAMPION, A., CASEY, P. G., FIELD, D., COTTER, P. D., HILL, C. & ROSS, R. P. 2013. In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice. BMC Microbiology, 13:23, 1-8. http://dx.doi.org/10.1186/1471-2180-13-23